Shengmai San for Treatment of Cardiotoxicity from Anthracyclines:A Systematic Review and Meta-Analysis

作     者：ZHANG Xiao-nan LI Yan-yang ZHANG Yuan-hui ZHANG Wan-qin ZHU Ya-ping ZHANG Jun-ping LV Shi-chao LIU Long-tao 

作者机构：National Clinical Research Center for Chinese Medicine CardiologyXiyuan HospitalChina Academy of Chinese Medical SciencesBeijing100091China Tianjin Medical University Cancer Institute and HospitalTianjin300060China First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin300112China 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2022年第28卷第4期

页      面：374-383页

核心收录：

学科分类：1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 1002[医学-临床医学] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(No.81973689,No.82074254) the Beijing Natural Science Foundation of China(No.7202176) 

主　　题：Shengmai San anthracyclines cardiotoxicity systematic review meta-analysis 

摘      要：Objective:To systematically evaluate the efficacy of Shengmai San in patients with cardiotoxicity of ***:Randomized controlled trials(RCTs)were identified by searching China National Knowledge Infrastructure(CNKI),Wanfang Database,Chinese Biomedical Literature Database(CBM),Pub Med,Cochrane Library,and Embase Databases from the inceptions until December *** Cochrane Handbook was used to evaluate the risk of bias in the included *** analysis was conducted using Rev Man 5.3 ***:Totally 19 RCTs with 2,331 participants were included in this *** showed that in improving arrhythmia(13 RCTs,n=1,877,RR=0.37,95%CI 0.25 to 0.52,P0.00001),the treatment group was superior to the control *** terms of reducing left ventricular end-diastolic diameter(LVEDD,2 RCTs,n=128,MD=-0.79,95%CI-0.93 to-0.65,P0.00001)and left ventricular end systolic diameter(LVESD,2 RCTs,n=128,MD=-0.58,95%CI-0.82 to-0.35,P0.00001),the treatment group was also better than the control *** reducing myocardial enzymes such as creatine kinase(CK)[(3 RCTs,n=256,SMD=-0.80,95%CI-1.16 to-0.44,P0.0001),(2 RCTs,n=126,SMD=-0.62,95%CI-0.98 to-0.26,P=0.0007)],the treatment group was superior to the control ***:Shengmai San has a positive effect on the treatment of cardiotoxicity from ***,in the future,it is still necessary to conduct high-quality RCTs to verify its efficacy.